21.20p+0.20 (+0.95%)28 Mar 2024, 12:34
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Oncimmune Holdings PLC Fundamentals

Company NameOncimmune Holdings PLCLast Updated2024-03-28
IndustryBiotechnologySectorHealthcare
Shares in Issue74.142 mMarket Cap£15.72 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£0.06EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.6284Debt Equity Ratio7.5632
Asset Equity Ratio12.8402Cash Equity Ratio4.8843
Quick Ratio3.6083Current Ratio3.91
Price To Book Value23.9234ROCE0

Oncimmune Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oncimmune Holdings PLC Company Financials

Assets202320222021
Tangible Assets£591,000.00£1.34 m£1.59 m
Intangible Assets£2.06 m£4.59 m£5.69 m
Investments000
Total Fixed Assets£2.87 m£6.55 m£8.22 m
Stocks£235,000.00£430,000.00£143,000.00
Debtors£1.92 m£1.36 m£1.64 m
Cash & Equivalents£3.21 m£1.43 m£8.63 m
Other Assets000
Total Assets£8.44 m£10.16 m£19.36 m
Liabilities202320222021
Creditors within 1 year£1.42 m£7.82 m£4.85 m
Creditors after 1 year£6.36 m£6.52 m£9.28 m
Other Liabilities000
Total Liabilities£7.78 m£14.34 m£14.13 m
Net assets£657,000.00-£4.18 m£5.23 m
Equity202320222021
Called up share capital£741,000.00£695,000.00£691,000.00
Share Premium£42.68 m£40.63 m£40.50 m
Profit / Loss-£5.93 m-£6.58 m-£6.06 m
Other Equity£657,000.00-£4.18 m£5.23 m
Preference & Minorities000
Total Capital Employed£657,000.00-£4.18 m£5.23 m
Ratios202320222021
Debt Ratio£0.88£0.570
Debt-to-Equity£7.56£1.320
Assets / Equity12.840212.840212.8402
Cash / Equity4.88434.88434.8843
EPS-£0.08-£0.10-£0.08
Cash Flow202320222021
Cash from operating activities-£6.79 m-£6.87 m-£4.53 m
Cashflow before financing-£9.81 m-£6.22 m£5.25 m
Increase in Cash£1.78 m-£7.15 m£4.40 m
Income202320222021
Turnover£1.15 m£2.32 m£3.72 m
Cost of sales£360,000.00£1.12 m£865,000.00
Gross Profit£792,000.00£1.20 m£2.86 m
Operating Profit-£3.92 m-£6.29 m-£5.14 m
Pre-Tax profit-£5.93 m-£6.58 m-£6.06 m

Oncimmune Holdings PLC Company Background

SectorHealthcare
ActivitiesOncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.
Latest Interim Date31 May 2023
Latest Fiscal Year End Date29 Feb 2024

Oncimmune Holdings PLC Directors

AppointedNamePosition
2016-11-07Mr. Andrew Vaughan UnittNon-Executive Director
2020-05-04Mr. Richard Simon SharpNon-Executive Director
2024-03-01Mr. Alistair MacdonaldNon-Executive Director,Chairman
2022-07-08Mr. Meinhard Folkert SchmidtNon-Executive Director,Chairman
2020-06-04Mr. Geoffrey Neil Hamilton-FairleyNon-Executive Director,Vice Chairman
2016-06-06Mr. Robert Hoyles PageExecutive Director,Chief Financial Officer
2023-10-12Mr. Timothy Brian BuntingNon-Executive Director,Deputy Chairman
2019-11-05Mr. Andrew MilletExecutive Director,Chief Financial Officer and Company Secretary
2020-06-04Mr. Carsten SchroederNon-Executive Director
2023-07-12Dr. Adam Mark HillExecutive Director,Chief Executive Officer
2021-01-19Dr. To CheungNon-Executive Director
2022-11-04Mr. Matthew HallExecutive Director,Chief Financial Officer
2024-03-01Mr. John Howard GooldNon-Executive Director
2023-12-11Mr. Martin John GouldstoneExecutive Director,Chief Executive Officer

Oncimmune Holdings PLC Contact Details

Company NameOncimmune Holdings PLC
AddressHucknall Road, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB
Telephone
Websitehttps://www.oncimmune.com

Oncimmune Holdings PLC Advisors

Nominated AdviserZeus Capital Ltd
Phone+44 2038295000
AuditorGrant Thornton (UK) LLP
Phone+44 1908660666
Fax+44 1908690180
StockbrokerZeus Capital Ltd
Phone+44 2038295000
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorPeachey & Co LLP
Phone(020) 7316 5200
Fax(020) 7316 5222